Otros idiomas Ascentage Pharma Group International

Acciones

6855

KYG0519B1023

Mercado cerrado - Hong Kong S.E. Otros sitios de cotización 10:09:00 03/05/2024			Varia. Cinco días.	Varia. 1 de enero.
18,4 ^HKD	-1,81 %		+4,43 %	-32,60 %

25/04	Ascentage Pharma presentará cuatro estudios en una reunión sobre oncología en EE.UU.	MT
09/04	El presidente de Ascentage Pharma aumenta su participación en la empresa	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Ascentage Pharma to Present Four Studies at US Oncology Meet	25/04
Ascentage Pharma Chairman Boosts Stake in Firm	09/04
Ascentage Pharma Group Directors Acquire Company Shares	04/04
Ascentage Pharma Widens Loss by Nearly 5% in 2023	28/03
Ascentage Pharma Announces 2023 Annual Results	28/03
Ascentage Pharma Group International Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Ascentage Pharma to Present Preclinical Results of Three Anti-Tumor Drugs at US Cancer Meet	06/03
Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting	06/03
Ascentage Pharma's Phase 3 Trial for Chronic Myeloid Leukemia Treatment Gets US FDA Nod; Shares Rise 3%	14/02
Global Registrational Phase III Study of Olverembatinib (HQP1351) Cleared by FDA	14/02
Ascentage Pharma Receives Clearance from the US Food and Drug Administration to Initiate Global Registrational Phase III Trial of Olverembatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia	14/02
Ascentage Pharma Trustee Buys 100,000 Shares	05/02
Ascentage Pharma Announces Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia Management from the National Comprehensive Cancer Network	17/01
Ascentage Pharma to Present at 42nd J.P. Morgan Healthcare Conference	02/01
Ascentage Pharma Group International Presents Preliminary Results from A Phase II Study of Novel Drug Candidate, Olverembatinib	15/12
Live from ASH 2023, Ascentage Pharma Releases the First Dataset of Bcl-2 Inhibitor Lisaftoclax in Patients with R/R MM, Demonstrating Encouraging ORR and VGPR	12/12
Live from ASH 2023, Ascentage Pharma Presents Updated Data from US Study of Olverembatinib, Further Validating Encouraging Efficacy in Patients Resistant to Ponatinib or Asciminib	12/12
Live from ASH 2023, Ascentage Pharma Releases Encouraging Long-Term Data of Bcl-2 Inhibitor Lisaftoclax in R/R CLL, Including an ORR of 73.3%	12/12
Ascentage Pharma Group International Releases the First Dataset of BCL-2 Inhibitor Lisaftoclax in Patients with R/R Mm, Demonstrating Encouraging ORR and VGPR	11/12
Small Lymphocytic Lymphoma Pipeline, FDA Approvals, Clinical Trials Developments, Companies 2023 \| Loxo Oncology, Chia Tai Tianqing Pharmaceutical Group, Iovance Biotherapeutics, and others.	05/12

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Ascentage Pharma Group International

Acciones

6855

KYG0519B1023

Otros idiomas

Filtros